428 related articles for article (PubMed ID: 31014129)
1. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
2. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
3. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
[TBL] [Abstract][Full Text] [Related]
4. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
6. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
7. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
Eedara BB; Rangnekar B; Doyle C; Cavallaro A; Das SC
Int J Pharm; 2018 May; 542(1-2):72-81. PubMed ID: 29524618
[TBL] [Abstract][Full Text] [Related]
8. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
9. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.
Momin MAM; Rangnekar B; Sinha S; Cheung CY; Cook GM; Das SC
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581469
[TBL] [Abstract][Full Text] [Related]
10. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
12. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
13. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
[TBL] [Abstract][Full Text] [Related]
15. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
16. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
17. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
Jong T; Li J; Morton DA; Zhou QT; Larson I
J Pharm Sci; 2016 Mar; 105(3):1156-63. PubMed ID: 26886330
[TBL] [Abstract][Full Text] [Related]
19. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
20. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
